CIDALIX

This brand name is authorized in Nigeria.

Active ingredients

The drug CIDALIX contains one active pharmaceutical ingredient (API):

1	Azithromycin UNII 5FD1131I7S - AZITHROMYCIN DIHYDRATE
	Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50S sub-unit and inhibition of peptide translocation.
	Read more about Azithromycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-0661	Suspension	CIDALIX ORAL SUSPENSION SUSP 200 mg/5 mL 20ml,60ml	CIDALIX ORAL SUSPENSION 20MG AZITHROMYCIN SUSPENSION 20MG AZITHROMYCIN ORAL SUSPENSION 20MG B4-0661 Drugs Imported Products 20ml,60ml Prescription Only Medicine (POM) 21/10/2019 TAMAR & PHAREZ NIG LTD, NYERE STREET, NARAYI H/COST KADUNA KADUNA SOUTH KADUNA 8030524857 tamphar@gmail.com BRAWN LABORATORIES LIMITED, PLOT NO. 13, N.I.T FARIDABAD 121001 ( HARYANA ) INDIA., India	26/04/2023
C4-1442	Dispersible tablet	Cidalix-100 Dispersible Tablet TAB_ORALLY_DIS 100 mg	Dispersible tablet	21/12/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FA10	Azithromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-0661, C4-1442